Health Canada approved Eydenzelt, a biosimilar of Eylea, for multiple ophthalmic indications, based on comprehensive evidence including a phase 3 trial. The phase 3 trial demonstrated Eydenzelt's ...

Expert retina and uveitis specialists will help support the growth and innovation of ANI’s ophthalmology and retina franchise ...

The 5th Eye Care Summit for the Middle East, Africa, and Russia (MEAR) region, under the patronage of AbbVie, the global ...

Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...

On the innovative side, there are ongoing trials for combining therapies—anti-VEGF plus steroids or laser—to get better and faster outcomes. AI-assisted retina exams are enabling doctors to detect DME ...

Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system ...

An oral HIV drug helped patients with center-involved diabetic macular edema achieve improvements in visual acuity, according ...

While shares of Regeneron Pharmaceuticals are climbing this month, investors shouldn't find the stock too pricey, as it's ...

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

Johnson & Johnson entered into a definitive agreement to acquire Halda Therapeutics OpCo for $3.05 billion in cash. Eli Lilly announced it will pay $40 million upfront and up to $2.56 billion in a ...